Genetic Markers in Triple-Negative Breast Cancer

Clinical Breast Cancer
Zuzana SporikovaMarian Hajduch

Abstract

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and is characterized by the absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Though TNBC is a highly heterogenic and aggressive disease, TNBC patients have better response to neoadjuvant therapy compared to other breast cancer subtypes. Nevertheless, patients with residual disease have a very poor prognosis, with higher probability of relapse and lower overall survival in the first years after diagnosis. TNBC has 6 subtypes with distinct molecular signatures with different prognoses and probably different responses to therapy. The precise stratification of TNBC is therefore crucial for the development of potent standardized and targeted therapies. In spite of intensive research into finding new molecular biomarkers and designing personalized therapeutic approaches, BRCA mutational status is the only clinically validated biomarker for personalized therapy in TNBC. Recent studies have reported several promising biomarkers that are currently being validated through clinical trials. The objective of this review was to summarize the clinically relevant genetic markers for TNBC that could serve as diagnostic, prognosti...Continue Reading

Citations

Mar 16, 2019·Journal of Cellular Biochemistry·Xiaomeng LiuGuochao Zhang
Apr 15, 2020·Scientific Reports·Abderrahim El GuerrabCorinne Aubel
May 14, 2019·Journal of X-ray Science and Technology·Hong-Xia ZhangGuo-Qun Mao
Oct 1, 2020·Therapeutic Advances in Medical Oncology·Kevin J LeeNatalie R Gassman
Jul 19, 2020·Pathology Oncology Research : POR·Hulya Sahin OzkanHandan Kaya
Oct 20, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·T J ThomasC K S Pillai
Dec 12, 2020·Critical Reviews in Oncology/hematology·Hussein SabitManel Esteller
Jan 19, 2021·Journal of Oral and Maxillofacial Pathology : JOMFP·J GowthamiDaffney Mano Doss
Dec 17, 2020·Journal of Personalized Medicine·Ioana-Ecaterina PraleaCristina-Adela Iuga
Jan 27, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David S HongManish R Patel
Apr 12, 2021·Neoplasia : an International Journal for Oncology Research·Jeremy JohnsonPiotr Rychahou
Jul 2, 2021·International Journal of Pharmaceutics·Rahul ChadarPrashant Kesharwani
Aug 30, 2021·The Breast : Official Journal of the European Society of Mastology·Ximu SunZhuo Ma
Nov 19, 2021·Expert Opinion on Investigational Drugs·Alessandro Rizzo, Angela Dalia Ricci
Nov 23, 2021·Expert Opinion on Investigational Drugs·Alessandro RizzoGennaro Gadaleta-Caldarola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Journal of Cancer Research and Clinical Oncology
Nami YamashitaYoshihiko Maehara
Annals of Oncology : Official Journal of the European Society for Medical Oncology
F Penault-Llorca, Giuseppe Viale
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Cornelia LiedtkeLajos Pusztai
Current Opinion in Obstetrics & Gynecology
Kim M Hirshfield, Shridar Ganesan
© 2022 Meta ULC. All rights reserved